体重减轻对超重/肥胖的年轻心力衰竭患者的预后影响
Shan He1, Xiaonan Guan1, Jianjun Zhang1
1From the Department of Heart Center, Beijing Chaoyang Hospital Jingxi Branch, Capital Medical University, Beijing, China.
Saudi medical journal
|April 24, 2024
概括
超重/肥胖和心力衰竭 (HF) 的年轻人显著减肥 (WL) 与HF和主要不良心脏事件 (MACE) 的住院减少有关. 这表明这些患者的预后可能更好.
科学领域:
- 心脏病学 心脏病学
- 代谢障碍 代谢障碍 代谢障碍
- 临床研究 临床研究
背景情况:
- 患有超重/肥胖 (OW/OB) 的年轻人的心力衰竭 (HF) 提出了独特的挑战.
- 在这个特定的人群中,减肥 (WL) 的预后影响尚未得到充分证实.
研究的目的:
- 调查显著的WL和主要心脏不良事件 (MACE) 在年轻的OW/OB患有HF的患者发生率之间的关联.
- 为了确定WL是否影响心脏病死亡率和HF再住院率.
主要方法:
- 研究了一组191名患有OW/OB和HF的年轻患者 (<45岁).
- 患者根据在出院后一年达到≥5%的WL而被分类.
- 主要心脏不良事件 (MACEs),包括心脏死亡和HF再住院,在一年内被跟踪.
主要成果:
- 47名患者实现了显著的WL. 患有WL的人患缺血性心脏病,阻塞性睡眠呼吸暂停,BMI和血压的比率更高.
- 两组之间没有观察到心脏死亡率的显著差异.
- 显著的WL独立相关于减少HF再入院 (HR=0.32) 和整体MACEs (HR=0.37).
结论:
- 显著的体重减轻似乎与患有心力衰竭的年轻超重/肥胖患者的良好预后有关.
- WL可能是一个可修改的因素,有助于改善这一患者群体的治疗结果.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Exercise and Cardiovascular Response
792
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
792
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Heart Failure Drugs: Inotropic Agents
574
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422


